Deutsche Bank biotech analyst Robyn Karnauskas told her clients in a quick email that she believed the Medicare meeting assessing Provenge would be positive for Dendreon because the questions were in-line with expectations; the panel will only be using publically available data; and Provenge has shown an overall survival benefit and has no side effects. --Written by Adam Feuerstein in Boston. >To contact the writer of this article, click here: Adam Feuerstein. >To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein. >To submit a news tip, send an email to: email@example.com.